Trending at Lumira Ventures

Zymeworks Announces the Successful Achievement of a Milestone with Lilly in Bi-Specific Antibody Therapeutics Collaboration

admin Portfolio News, Zymeworks

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. today announced the successful achievement of a research milestone in its collaboration with Eli Lilly and Company in the development of a novel immune-modulating bi-specific antibody using Zymeworks’ proprietary Azymetric™ platform. In accordance with the …

Zymeworks and Kairos Therapeutics Enter into Strategic Partnership and Optional Merger Agreement to Develop Antibody Drug Conjugates and Bi-Specific Antibodies

admin Portfolio News, Zymeworks

Vancouver, Canada – January 8, 2016: Zymeworks Inc. and Kairos Therapeutics Inc., both privately-held biotech companies headquartered in Vancouver, today announced they have entered into a strategic partnership whereby Zymeworks, a leader in the development of bi-specific and multi-specific antibodies, …